Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - kyntheum
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp32bfd365b84c64d962132c327f20aa6e
identifier: http://ema.europa.eu/identifier
/EU/1/16/1155/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Kyntheum 210 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-32bfd365b84c64d962132c327f20aa6e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/16/1155/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - kyntheum
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Kyntheum contains the active substance brodalumab. Brodalumab is a monoclonal antibody, a specialised type of protein that recognises and attaches to certain proteins in the body.
Brodalumab belongs to a group of medicines called interleukin (IL) inhibitors. This medicine works by blocking the activity of IL-17 proteins, which are present at increased levels in diseases such as psoriasis.
Kyntheum is used to treat a skin condition called plaque psoriasis , which causes inflammation and scaly plaque formation on the skin. Kyntheum is used in adults with moderate to severe plaque psoriasis affecting large areas of the body.
Using Kyntheum will benefit you by leading to improvements of skin clearance and reducing psoriasis signs and symptoms, such as itch, redness, scaling, burning, stinging, cracking, flaking and pain.
Do not use Kyntheum
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before using Kyntheum:
if you have an inflammatory disease affecting the gut named Crohn s disease
if you have an inflammation of the large intestine named ulcerative colitis
if you have ever had or are having suicidal thoughts or actions, depression, anxiety, or mood problems
if you have an infection now or often get infections eDoc-000624731 - Version 28. 0
if you have a long-term (chronic) infection
if you have tuberculosis (TB), have had a positive TB test, or have been in close contact with someone with TB. You may be treated with another medicine for TB before you begin treatment with Kyntheum
if you have recently received or are scheduled to receive a vaccination. You should not be given certain types of vaccines (called live vaccines ) while being treated with Kyntheum
if you have used Kyntheum during the last three months of your pregnancy, you should talk to your doctor before vaccinating your baby
if you are receiving any other treatment for psoriasis, such as another immunosuppressant or phototherapy with ultraviolet (UV) light.
After starting Kyntheum, tell your doctor, pharmacist or nurse immediately:
Inflammatory bowel disease (Crohn s disease or ulcerative colitis) Stop using Kyntheum and tell your doctor or seek medical help immediately if you notice abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (any signs of bowel problems).
Look out for allergic reactions Kyntheum can potentially cause serious side effects, including allergic reactions. You must look out for signs of these conditions while you are taking Kyntheum.
Stop using Kyntheum and tell your doctor or seek medical help immediately if you notice any signs indicating an allergic reaction. Such signs are listed under Serious side effects in section 4. Children and adolescents Kyntheum is not recommended for children and adolescents (below 18 years of age) because it has not been studied in this age group.
Other medicines and Kyntheum Tell your doctor or pharmacist:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Kyntheum has not been tested in pregnant women and it is not known if this medicine can harm your unborn baby. It is therefore preferable to avoid the use of Kyntheum during pregnancy. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use adequate contraception while using Kyntheum and for at least 12 weeks after the last dose of Kyntheum.
It is not known whether brodalumab passes into breast milk. Tell your doctor if you are breast-feeding or plan to breast-feed. Your doctor will then help you decide whether to stop breast-feeding or stop using Kyntheum. Together you will consider the benefit of breast-feeding to the baby and the benefit of Kyntheum to you.
Driving and using machines Kyntheum is unlikely to affect your ability to drive and use machines.
eDoc-000624731 - Version 28. 0
Kyntheum should be prescribed to you by a doctor with experience in diagnosing and treating psoriasis.
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.
How much Kyntheum is given
How is Kyntheum given Kyntheum is given as an injection under the skin (known as a subcutaneous injection).
Self-administration instructions See the detailed Instructions for Use that comes with this medicine for information on the right way to store, prepare, and give your injections at home.
If you use more Kyntheum than you should If you use more of this medicine than prescribed or take the dose sooner than required, tell your doctor.
If you forget to use Kyntheum If you have forgotten to inject a dose of Kyntheum, inject the next dose as soon as you can after the missed dose. Then, talk to your doctor about when you should inject the next dose. Do not take a double dose to make up for a forgotten dose.
If you stop using Kyntheum You should not stop using Kyntheum without speaking to your doctor first. If you stop treatment, symptoms of psoriasis may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
eDoc-000624731 - Version 28. 0
Serious side effects
Stop using Kyntheum and tell your doctor or seek medical help immediately if you get any of the following side effects. Your doctor will decide if and when you may restart the treatment:
Serious allergic reaction (may affect up to 1 in 1,000 people), the signs may include:
Possible serious infections (may affect up to 1 in 100 people), the signs may include:
Other side effects
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Most of these side effects are mild to moderate. If any of these side effects becomes severe, tell your doctor, nurse, or pharmacist.
Abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems) have also been reported with IL-17 inhibitors, such as Kyntheum.
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and label of the pre- filled syringe after EXP. The expiry date refers to the last day of that month.
Keep the pre-filled syringe in the outer carton in order to protect from light.
eDoc-000624731 - Version 28. 0
Store in a refrigerator (2 C to 8 C). Do not freeze.
Kyntheum can be kept at room temperature up to 25 C in the outer carton for 14 days. Throw away Kyntheum if it is not used within 14 days of storage at room temperature.
Do not use this medicine if you notice the solution is cloudy or discoloured or contains lumps, flakes or particles.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Kyntheum contains
What Kyntheum looks like and contents of the pack Kyntheum is a solution for injection that is a clear to slightly pearly, colourless to slightly yellow liquid, with no particles.
Kyntheum is available in unit packs containing 2 pre-filled syringes and in multipacks comprising 3 cartons, each containing 2 pre-filled syringes. Not all pack sizes may be marketed.
Marketing Authorisation Holder LEO Pharma A/S Industriparken DK-2750 Ballerup Denmark
Manufacturer Laboratoires LEO
39 route de Chartres 28500 Vernouillet France
LEO Pharma A/S Industriparken DK-2750 Ballerup Denmark
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien LEO Pharma N.V./S.A T l/Tel: +32 3 740 7Lietuva LEO Pharma A/S Tel: +45 44 94 58
LEO Pharma A/S Te .: +45 44 94 58 Luxembourg/Luxemburg LEO Pharma N.V./S.A T l/Tel: +32 3 740 7eDoc-000624731 - Version 28. 0
esk republika LEO Pharma s.r.o. Tel: +420 734 575 Magyarorsz g LEO Pharma A/S Tel: +45 44 94 58 Danmark LEO Pharma AB Tlf: +45 70 22 49 Malta LEO Pharma A/S Tel: +45 44 94 58 Deutschland LEO Pharma GmbH Tel: +49 6102 2Nederland LEO Pharma B.V. Tel: +31 205104Eesti LEO Pharma A/S Tel: +45 44 94 58 Norge LEO Pharma AS Tlf: +47 22514
LEO Pharmaceutical Hellas S.A. : +30 210 68 34 sterreich LEO Pharma GmbH Tel: +43 1 503 6Espa a Laboratorios LEO Pharma, S.A. Tel: +34 93 221 3Polska LEO Pharma Sp. z o.o. Tel.: +48 22 244 18 France Laboratoires LEO
T l: +33 1 3014 4Portugal LEO Farmac uticos Lda.
Tel: +351 21 711 0Hrvatska LEO Pharma A/S Tel: +45 44 94 58 Rom nia LEO Pharma A/S Tel: +45 44 94 58 Ireland LEO Laboratories Ltd Tel: +353 (0) 1 490 8Slovenija LEO Pharma A/S Tel: +45 44 94 58 sland Vistor hf. S mi: +354 535 7Slovensk republika LEO Pharma s.r.o. Tel: +420 734 575 Italia LEO Pharma S.p.A Tel: +39 06 52625Suomi/Finland LEO Pharma Oy Puh/Tel: +358 20 721 8
The Star Medicines Importers Co. Ltd. : +357 2537 1Sverige LEO Pharma AB Tel: +46 40 3522 Latvija LEO Pharma A/S Tel: +45 44 94 58 United Kingdom (Northern Ireland) LEO Laboratories Ltd Tel: +44 (0) 1844 347This leaflet was last revised in
eDoc-000624731 - Version 28. 0
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-32bfd365b84c64d962132c327f20aa6e
Resource Composition:
Generated Narrative: Composition composition-en-32bfd365b84c64d962132c327f20aa6e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/16/1155/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - kyntheum
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp32bfd365b84c64d962132c327f20aa6e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp32bfd365b84c64d962132c327f20aa6e
identifier:
http://ema.europa.eu/identifier
/EU/1/16/1155/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Kyntheum 210 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en